Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
NCT00274131
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
170
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson Disease
Interventions
DRUG:
Pramipexole 0.125 mg tablets
DRUG:
Pramipexole 0.5 mg tablets
Sponsor
Boehringer Ingelheim